LLY
Meme
Social trend and summarized meme
$796.28
+2.22% weekly
+3.71%
Last Hour Posts
+500.0%
2
Last 24hrs Posts
-66.7%
4
1hr Avg Sentiment
+100.0%
0.8943
24hrs Avg Sentiment
+123.6%
0.4472
Inst Hold: 84.0%
Short Pct: 0.7%
Sentiment vs. Performance
Updated 2024-12-23T23:38:00+00:00 browser time.
*
R500 ranks any stock, ETF, mutual fund, plus some crypto against all SP500 component stocks,
over a period of time, refreshed every 10 minutes.
The lower the R500 the better.
By default, R500 ranks over the latest trading day.
** Sum of post sentiment times post up votes
Rank LLY
Victory for Eli Lilly (LLY) as the FDA begins shutdown of competing pharmacies selling their powerhouse weight-loss drug.
Posted 2024-12-19T21:34:55, updated 2024-12-21T22:26:56 17 0.5845 stocks
You probably noticed that #1 and #2 are made by LLY. **Orforglipron** is their oral medication for people who don't like needled. **Retatrutide** shows even greater effectiveness than their alreading leading Tirzepatide, and will help them extend their patents.
Technical Analysis
**
Technical analysis summarizes recommendations from 11 oscillators and 15 moving average derivatives. Not advice and use at own risk.
| Oscillators | |||
|---|---|---|---|
| RSI | 50.87 | NEUTRAL | |
| Stoch.K | 22.82 | NEUTRAL | |
| CCI20 | -15.76 | NEUTRAL | |
| ADX | 16.75 | NEUTRAL | |
| AO | -10.94 | NEUTRAL | |
| Mom | -7.30 | BUY | |
| MACD.macd | -9.75 | BUY | |
| Stoch.RSI.K | 31.16 | NEUTRAL | |
| W.R | -53.35 | NEUTRAL | |
| BBPower | 5.11 | SELL | |
| UO | 38.80 | NEUTRAL | |
| Moving Averages | |||
|---|---|---|---|
| EMA10 | 781.80 | BUY | |
| SMA10 | 781.10 | BUY | |
| EMA20 | 788.08 | BUY | |
| SMA20 | 791.89 | BUY | |
| EMA30 | 796.33 | SELL | |
| SMA30 | 784.72 | BUY | |
| EMA50 | 813.54 | SELL | |
| SMA50 | 819.01 | SELL | |
| EMA100 | 832.62 | SELL | |
| SMA100 | 863.37 | SELL | |
| EMA200 | 808.23 | SELL | |
| SMA200 | 838.61 | SELL | |
| Ichimoku.BLine | 778.93 | NEUTRAL | |
| VWMA | 787.59 | BUY | |
| HullMA9 | 767.08 | BUY | |
Most recent 2024-12-23T23:04:15+00:00
NVO price action is concerning 1 0.8695 stocks
Nvo is my worst performer in terms of percentage. glad i only have $17 invested in it. I trimmed m...
- I trimmed my lly around $945 and $830 and sold out hims, ozem, hrtz.
- i'm currently holding LLY, PFE, MRK, LNTH, AZN, NOVATIS, VERTEX AND NTRA
- I chose healthcare to balance out my portfolio but they have been underperforming for last 3 to 4years.
- Those 4 have signs of recover and they have good dividends.
Novo Nordisk experienced the most insane one-day movement, seemingly based on nothing. 1 0.9192 wallstreetbets
That is definitely impressive but it's also worth considering that there's a significant back and fo...
- That is definitely impressive but it's also worth considering that there's a significant back and forth movement happening here.
- It's inevitable that other players enter the space quickly and eat up market share.
- Perhaps more importantly, as stocks, they differ greatly.
- The PE and PEG on LLY are significantly higher than NVO.
- Even if NVO continued to lose market share, it's entirely possible the stock performs better because expectations are significantly lower.
2 days ago 2024-12-21T13:34:27+00:00
NVO price action is concerning 2 0.9766 stocks
Food for thought: LLY's next drug retatrutide is performing very well in trials, whilst NVO's hopefu...
- Food for thought: LLY's next drug retatrutide is performing very well in trials, whilst NVO's hopeful competitor, CagriSema, just had a moderate underperformance vs expectation in trials.
- Mounjaro/zepbound is already the better drug than ozempic/wegovy, and LLY seems to be securing the same dynamic for the next generation.
- The brand name of "ozempic" has carried NVO far, even while a better drug was available (mounjaro).
- They're losing the efficacy battle and their branding superiority is about to be moot with the next generation.
- LLY is the easy favorite in the obesity business.
I feel like I'm already addicted to options/trading at 18 and it's ruining my life 1 0.8873 wallstreetbets
the worst part about this story is you've just described my life. i thought ill invest in spy and ch...
- i thought ill invest in spy and chill, then i was like lemme wheel companies, it worked well w spy, nvda, lly, now, UNTIL STUPID LLY FELL MAD.
- i decided to 0dte spy, and i saw a 100% gain ($500) and i honestly had no idea wtf i did.
- , but ever since, i've just been doing options based off of WSB without reading fundas.
- i bought uber puts because the graph matched the environment of a beach (posted recently, got 87% gains or so on that)
- there's no going back till i hit 10 mil, or 0. it's prolly 0. every paycheck keeps going towards options.
4 days ago 2024-12-19T21:58:00+00:00
Victory for Eli Lilly (LLY) as the FDA begins shutdown of competing pharmacies selling their powerhouse weight-loss drug. 25 0.9777 stocks
LLY has a strong future with Zepound being proven by side by side studies as the best weight loss dr...
- As broad market downturn will likely drag LLY down with it as biopharma is a more speculative industry.
- They are also working on their own improved obesity drug cagrisema which looks to be roughly as effective as Retratutide.
- They are also working on getting their own semaglutide drugs approved for treating Alzheimer's, potentially competing more with LLY.
- #1 benefit of Novo as an invest is a much lower PE and easier buy in stock price.
- Also does LLY have a phase 2-3 oral obesity drug?
NVO price action is concerning 13 0.9752 stocks
I monitor both LLY and NVO since the day I know about these two companies. Whenever they are down, I...
- Do not see price action, if you invest these companies, just buy them when they are crashed like today.
- In fact, I purchased pre-market and market hours NVOX (2x of NVO) as I expect them to recover.
- Reason: The drug test proved 22% weight reduction success while market is expecting 25%.
- Don't you think it is silly issue as NVO can capture the market with price competitiveness.
- Any way, any drop in price, in good companies, are opportunity to buy more.
Victory for Eli Lilly (LLY) as the FDA begins shutdown of competing pharmacies selling their powerhouse weight-loss drug. 3 0.9499 stocks
No, not yet at least. It makes little sense to me why HIMS was down over 8% when their compounded dr...
- It makes little sense to me why HIMS was down over 8% when their compounded drug is still technically flowing, but LLY is still stagnate (for now) with this fantastic news their compounding competition has to cease.
- HIMS and Wegovy/Ozempic are still sexy namebrands the market recognizes.
- Plus, for all we know the FDA won't go after Semaglutide for a couple months (new administration).
- I'm not very experienced though.
- I'm confident in LLY but not the inverse.
Victory for Eli Lilly (LLY) as the FDA begins shutdown of competing pharmacies selling their powerhouse weight-loss drug. 17 0.5845 stocks
You probably noticed that #1 and #2 are made by LLY. **Orforglipron** is their oral medication for p...
- **Retatrutide** shows even greater effectiveness than their alreading leading Tirzepatide, and will help them extend their patents.
6 days ago 2024-12-17T06:00:40+00:00
Eli Lilly (LLY) or Novo Nordisk (NVO)? 2 0.956 stocks
I recently started investing in both companies. I'm 90% weighted towards NVO and 10% weighted toward...
- Even if Mounjaro and Zepbound are better than Wegovy and Ozempic, I think NVO will be fine.
- The company overall has such an impressive balance sheet and performs so well financially in every aspect.
- I don't suspect the growth will stop if LLY's new round of medication is better.
- I think the growth will slow, but NVO will get back on track and make a better drug in the near future.
- For now, I'm dollar cost averaging into both companies at a 90/10 NVO to LLY ratio.
Day-by-day Polarity
| Date** | Open | High | Low | Close or Current | R500* | Mentions | Positive Mentions | Up Votes | Voted Sentiment** |
|---|---|---|---|---|---|---|---|---|---|
| Mon 2024/12/23 | +2.27% | +4.12% | +0.69% | +3.71% $796.28 | #6 | 1 | 1 | 1 | 0.00 |
| Sun 2024/12/22 | 5 | 5 | 5 | 1.74 | |||||
| Sat 2024/12/21 | 7 | 6 | 17 | 14.16 | |||||
| Fri 2024/12/20 | +7.10% | +7.10% | +1.20% | +1.35% $767.76 | #239 | 51 | 38 | 67 | 6.67 |
| Thu 2024/12/19 | +0.05% | +1.08% | -1.61% | -0.94% $757.54 | #343 | 11 | 9 | 55 | 39.75 |
| Wed 2024/12/18 | -0.46% | +0.05% | -2.07% | -1.79% $764.71 | #112 | 2 | 1 | 2 | 0.02 |
| Tue 2024/12/17 | -0.15% | +1.16% | -0.84% | -0.05% $778.62 | #134 | 4 | 4 | 5 | 2.43 |
| Mon 2024/12/16 | +0.36% | +1.35% | -1.76% | -1.28% $779.00 | #398 | 1 | 1 | 0 | 0.00 |
| Sun 2024/12/15 | 1 | 1 | 1 | 0.92 | |||||
| Sat 2024/12/14 | 2 | 2 | 2 | 0.57 | |||||
| Fri 2024/12/13 | -0.67% | +1.52% | -1.20% | +0.87% $789.12 | #43 | 1 | 1 | 1 | 0.00 |
| Thu 2024/12/12 | +0.09% | +0.73% | -2.22% | -1.72% $782.35 | #455 | 8 | 7 | 8 | 0.46 |
| Wed 2024/12/11 | -0.54% | -0.01% | -1.65% | -0.44% $796.03 | #316 | 1 | 0 | 1 | -0.86 |
| Tue 2024/12/10 | +0.71% | +1.30% | -0.82% | -0.50% $799.58 | #239 | None | 0 | None | |
| Mon 2024/12/09 | -0.36% | -0.36% | -3.08% | -2.80% $803.58 | #463 | 2 | 2 | 2 | 0.81 |
| Sun 2024/12/08 | 2 | 1 | 2 | 0.46 | |||||
| Sat 2024/12/07 | 1 | 0 | 1 | -0.55 | |||||
| Fri 2024/12/06 | +0.25% | +1.86% | +0.01% | +0.13% $826.71 | #180 | None | 0 | None | |
| Thu 2024/12/05 | -0.25% | +0.16% | -1.49% | -0.51% $825.62 | #267 | None | 0 | None | |
| Wed 2024/12/04 | +1.82% | +4.07% | +0.88% | +2.03% $829.84 | #43 | None | 0 | None | |
| Tue 2024/12/03 | +0.39% | +2.17% | +0.23% | +1.69% $813.33 | #18 | 1 | 1 | 1 | 0.15 |
| Mon 2024/12/02 | +0.35% | +1.26% | -0.02% | +0.56% $799.80 | #120 | 8 | 8 | 8 | 0.63 |
| Sun 2024/12/01 | 3 | 2 | 6 | -1.69 | |||||
| Sat 2024/11/30 | 2 | 1 | 6 | 0.33 | |||||
| Fri 2024/11/29 | +0.40% | +1.54% | +0.14% | +0.91% $795.35 | #95 | None | 0 | None | |
| Thu 2024/11/28 | 2 | 2 | 148 | 138.36 | |||||
| Wed 2024/11/27 | -0.15% | +0.70% | -1.14% | -0.14% $788.19 | #303 | 3 | 3 | 3 | 0.35 |
| Tue 2024/11/26 | +4.00% | +6.89% | +2.51% | +4.55% $789.32 | #6 | 19 | 13 | 28 | 9.77 |
| Mon 2024/11/25 | +0.27% | +0.93% | -1.07% | +0.93% $755.00 | #234 | 1 | 1 | 1 | 0.00 |
| Sat 2024/11/23 | 2 | 0 | 3 | -2.04 | |||||
| Fri 2024/11/22 | +0.95% | +1.51% | -0.65% | -0.25% $748.01 | #419 | 1 | 1 | 1 | 0.00 |
| Thu 2024/11/21 | -0.97% | -0.05% | -2.44% | -0.46% $749.92 | #467 | 1 | 1 | 1 | 0.00 |
| Wed 2024/11/20 | +0.83% | +3.79% | +0.79% | +3.25% $753.41 | #15 | 17 | 12 | 28 | 1.45 |
| Tue 2024/11/19 | -1.50% | +0.39% | -2.03% | +0.35% $729.73 | #138 | 21 | 16 | 32 | 0.91 |
| Mon 2024/11/18 | -1.74% | -1.63% | -4.66% | -2.55% $727.20 | #496 | 21 | 13 | 22 | 0.08 |
| Sun 2024/11/17 | 3 | 2 | 3 | -0.56 | |||||
| Sat 2024/11/16 | 7 | 4 | 6 | 0.08 | |||||
| Fri 2024/11/15 | -1.40% | -1.05% | -5.35% | -5.09% $746.20 | #488 | 4 | 1 | 8 | -2.17 |
| Thu 2024/11/14 | -0.32% | -0.32% | -3.49% | -3.15% $786.23 | #478 | 5 | 2 | 9 | 2.51 |
| Wed 2024/11/13 | +0.18% | +1.25% | -0.92% | -0.86% $811.81 | #404 | 1 | 1 | 1 | 0.08 |
| Tue 2024/11/12 | -0.27% | +0.19% | -2.61% | -1.63% $818.86 | #404 | 3 | 2 | 4 | -1.15 |
| Mon 2024/11/11 | -0.03% | +1.50% | -0.83% | +0.11% $832.44 | #296 | 5 | 5 | 5 | 0.15 |
| Sun 2024/11/10 | 2 | 1 | 3 | 1.68 | |||||
| Sat 2024/11/09 | 5 | 5 | 7 | 2.87 | |||||
| Fri 2024/11/08 | +0.76% | +6.25% | +0.48% | +4.27% $831.54 | #13 | 24 | 18 | 27 | 0.71 |
| Thu 2024/11/07 | +1.07% | +3.37% | +0.23% | +2.71% $797.45 | #38 | 16 | 9 | 18 | -4.55 |
| Wed 2024/11/06 | +1.40% | +1.82% | -4.77% | -3.68% $776.38 | #470 | 24 | 15 | 28 | -0.79 |
| Tue 2024/11/05 | -0.29% | +0.38% | -1.07% | -0.01% $806.06 | #446 | 5 | 5 | 5 | 1.04 |
| Mon 2024/11/04 | -1.70% | +0.15% | -1.86% | -1.56% $806.14 | #461 | 3 | 1 | 11 | -7.77 |
| Sun 2024/11/03 | 1 | 1 | 1 | 0.44 | |||||
| Sat 2024/11/02 | 1 | 0 | 3 | -2.15 | |||||
| Fri 2024/11/01 | -0.21% | +0.39% | -1.57% | -1.30% $818.93 | #421 | 5 | 2 | 5 | -0.23 |
| Thu 2024/10/31 | -1.22% | +0.79% | -2.55% | -2.02% $829.74 | #390 | 5 | 4 | 7 | -0.34 |
| Wed 2024/10/30 | -11.63% | -4.77% | -14.89% | -6.28% $846.83 | #494 | 51 | 36 | 99 | 10.02 |
| Tue 2024/10/29 | +0.29% | +1.38% | +0.29% | +0.89% $903.58 | #75 | 21 | 19 | 30 | -4.71 |
| Mon 2024/10/28 | +0.24% | +0.62% | -0.22% | +0.32% $895.59 | #287 | 1 | 1 | 1 | 0.00 |
| Sun 2024/10/27 | 3 | 3 | 3 | 0.63 | |||||
| Sat 2024/10/26 | 1 | 1 | 2 | 1.88 | |||||
| Fri 2024/10/25 | +0.94% | +1.08% | -0.21% | +0.15% $892.70 | #135 | 3 | 2 | 3 | -0.20 |